|
|
Volumn , Issue , 2009, Pages 406-413
|
|
What is the role of reduced-intensity transplantation in the treatment of older patients with AML?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
MYELOABLATIVE AGENT;
ACUTE DISEASE;
AGE;
AGED;
DONOR;
DRUG RESISTANCE;
FEMALE;
GENETICS;
GRAFT VERSUS HOST REACTION;
GRAFT VERSUS LEUKEMIA EFFECT;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
MALE;
METHODOLOGY;
MIDDLE AGED;
MULTIMODALITY CANCER THERAPY;
MYELOID LEUKEMIA;
PATHOLOGY;
PROGNOSIS;
RECURRENT DISEASE;
REMISSION;
REVIEW;
SURVIVAL;
TREATMENT OUTCOME;
ACUTE DISEASE;
AGE FACTORS;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
COMBINED MODALITY THERAPY;
DRUG RESISTANCE, NEOPLASM;
FEMALE;
GRAFT VS HOST DISEASE;
GRAFT VS LEUKEMIA EFFECT;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
LEUKEMIA, MYELOID;
MALE;
MIDDLE AGED;
MYELOABLATIVE AGONISTS;
PROGNOSIS;
RECURRENCE;
REMISSION INDUCTION;
SURVIVAL ANALYSIS;
TISSUE DONORS;
TRANSPLANTATION CONDITIONING;
TREATMENT OUTCOME;
|
|
EID: 77949458197
PISSN: None
EISSN: 15204383
Source Type: Journal
DOI: 10.1182/asheducation-2009.1.406 Document Type: Review |
|
Times cited : (11)
|
|
References (32)
|
